cbdMD to Present at ThinkEquity Conference on October 26, 2022, in New York City

By: Newsfile

Charlotte, North Carolina--(Newsfile Corp. - October 25, 2022) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted, and widely recognized CBD companies, announced today that the Company will present at the ThinkEquity Conference on Wednesday, October 26, 2022, at 12:30pm ET at the Mandarin Oriental Hotel in New York City. cbdMD's President Kevin MacDermott and Chief Financial Officer Ronan Kennedy will be conducting one-on-one meetings throughout the day.

The ThinkEquity Conference gathers industry insiders, investors, and leading executives from around the world. According to ThinkEquity, attendees can expect a full day of company presentations, panel discussions, one-on-one investor meetings and more. Featured sectors include EV/EV Infrastructure, AI/Big data technology, Biotechnology, Metals & Mining and Oil & Gas.

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and recognized hemp-derived cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, NSF Certified for Sport products, as well as Full Spectrum and Delta 9 THC products. The cbdMD brand currently includes high-quality, premium CBD products including tinctures, gummies, topicals, capsules, sleep aids and more. The Company's Paw CBD brand includes formulated pet products including tinctures, chews and topicals in varying strengths. cbdMD's full lineup of products are currently available to ship across the USA2 and to many countries worldwide3.

To learn more about cbdMD and the complete line of products, please visit www.cbdmd.com, check our LinkedIn page, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on cost reductions, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the "SEC") on December 17, 2021 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Contacts:

cbdMD, Inc.

Ronan Kennedy, CFO
+1 (704) 445-3064
IR@cbdmd.com

1 THC-free is defined as below the level of detection using validated scientific analytical tools.
2Unless otherwise limited by known state or local jurisdiction.
3Shipment outside of the United States is limited by the laws of the specific jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/141778

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.